On December 26, 2025, Zhejiang Tianyuan Biotechnology Co., Ltd., in partnership with Tailong Bank Haishu Sub-branch, successfully hosted a health public welfare sharing session. Ms. Zhu Youwu, Group Chief Administrative Officer, led the company team in warmly welcoming all attending guests.

      At the beginning of the event, guests were guided by professional docents through Tianyuan Biotech’s Science and Technology Exhibition Hall and laboratories. The extensive exhibits and advanced laboratory equipment vividly showcased the company’s technical strength and development journey in cutting-edge fields such as bio-health, providing attendees with an intuitive understanding of the mysteries of biotechnology.

      Following the tour, all participants gathered for a lively session. Witnessed by the guests, Ms. Jin Weisha, Vice President of Tailong Bank, and Mr. Jiao Mingming, General Manager of Tianyuan Biotech, signed a strategic cooperation agreement. This milestone marks a solid step forward for both parties in promoting bio-health knowledge and serving public health.

      After the signing ceremony, Mr. Yao Jincheng, Director of the Testing Laboratory, delivered an engaging lecture titled "Managing Sub-health Status to Sustain Vitality." Drawing from daily life examples, Director Yao explained in accessible terms the causes and risks of sub-health conditions, along with effective management strategies, offering practical health management insights to the audience.

      Additionally, Dr. Liu Guangcheng, Director of the Cell Laboratory, focused on current industry highlights with an in-depth interpretation of the "Cell Therapy Application Projects Approved in Hainan Boao Lecheng International Medical Tourism Pilot Zone." He comprehensively presented the company’s research advantages, highlighting the immense potential and broad prospects of cell therapy from a professional perspective.

      Mr. Chen Minjing, President of Tailong Bank, highly commended the successful hosting of the event and expressed his expectation for continued deepened cooperation between the two parties. He noted that this partnership represents an innovative integration of finance and bio-health, enabling the provision of more comprehensive health services and financial solutions for clients. Through this event, Tianyuan Biotech not only demonstrated its professional expertise in biotechnology to the public but also made positive contributions to raising public health awareness and disseminating scientific knowledge.

      Founded in 2017, Zhejiang Tianyuan Biotechnology Co., Ltd. is a national high-tech enterprise dedicated to cell research and development, manufacturing, operations, and services. The company possesses valuable resource banks, including an HLA Umbilical Cord Matching Bank, an iPS Seed Cell Bank, and a Tumor Cell Bank. It is also a participating unit in formulating the group standard for immune function assessment methods under the National Health Commission (NHC). Furthermore, Tianyuan Biotech has co-established the Joint Laboratory for Metabolic Immune Monitoring with the NHC Research Institute, and serves as key research service platforms such as the Ningbo Storage Center of the National Stem Cell Translational Resource Bank and the Achievement Transformation Center of the NHC Research Institute.